

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
10 May 2024 (10.05.2024)



(10) International Publication Number
WO 2024/094690 A1

(51) International Patent Classification:

A61K 39/42 (2006.01) *C07K 14/005* (2006.01)
A61K 39/44 (2006.01) *C07K 14/73* (2006.01)
A61K 38/17 (2006.01) *C07K 16/10* (2006.01)
A61P 31/18 (2006.01) *A61K 47/64* (2017.01)

(21) International Application Number:

PCT/EP2023/080353

(22) International Filing Date:

31 October 2023 (31.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/421,737 02 November 2022 (02.11.2022) US

(71) Applicant: **VIIV HEALTHCARE UK (NO.5) LIMITED** [GB/GB]; GSK, Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY (GB).

(72) Inventors: **ARNOULT, Eric**; c/o ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405 (US). **HU, Tiancen**; ViiV Healthcare, 36 East Industrial Road, Branford, Connecticut 06405 (US). **KRYSTAL, Mark R.**; ViiV

Healthcare, 36 East Industrial Road, Branford, Connecticut 06405 (US). **SCHAWALDER, James**; ViiV Healthcare, 410 Blackwell Street, Durham, North Carolina 27701 (US).


(74) Agent: **THORNLEY, Rachel**; GSK, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: ANTIGEN BINDING PROTEINS

FIG. 1



(57) Abstract: Antigen binding proteins of the invention bind to Human Immunodeficiency Virus (HIV) envelope protein and are useful in treating and preventing HIV infection. In particular, the antigen binding proteins bind to two different epitopes on HIV envelope surface glycoprotein 120 (gp120): the V3 loop region and the CD4 binding site.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*